Alexion bets $1.4B on Portola and its laggard bleeding drug Andexxa
Back in December, Alexion shot down an activist investor's request to put itself on the block. (Alexion)
Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors.
Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday.
That's $18 per share in cash—a 131% premium on Portola's Monday closing price of $7.76 per share.
Building a Flexible, Challenge Resistant and Patient Centric Clinical Supply Chain
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. In this webinar, learn the benefits of utilizing demand-led supply and direct-to-patient distribution models in the clinical supply chain, as well as how they can be used to both improve flexibility and better align with patient needs. Register today!
The Portola buyout will take Alexion beyond a rare-disease portfolio dominated by blockbuster C5-inhibitor Soliris and follow-up drug Ultomiris. The centerpiece of the deal is a bleeding reversal agent, Andexxa, designed for patients using two common anticoagulant drugs, Xarelto and Eliquis.
So far, Andexxa has delivered disappointing sales, but Alexion still sees promise—even if it'll take a while for that promise to pay off.
Execs were straightforward with analysts on a Monday call, saying the Portola buy would take time to add value given Andexxa's minuscule commercial penetration––around 3% in the factor Xa reversal agent market––and a raft of strategic changes yet to be rolled out.
"The way we look at value here is long-term value," CFO Aradhana Sarin told analysts. "This is a diversification play for us .. [and] we'll need to have a really heavy lift in the next few quarters and years to drive value here."
However, Alexion believes its commercial team can lean on a "near-complete overlap" between the healthcare providers its current sales and outreach teams now target and the potential market access points for Andexxa, CCO Brian Goff said. The Portola drug is used in emergencies in acute-care settings, and Soliris and Ultomiris are often first used in hospitalized patients.
Andexxa currently sports the FDA's approval to reverse the effects of severe bleeding in patients taking Johnson & Johnson and Bayer's Xarelto, or Bristol Myers Squibb and Pfizer's Eliquis. The drug's patents currently protect its market exclusivity through 2030, Alexion said.
In all, Alexion predicts that Andexxa could expand far beyond the 17.7 million patients treated in 2020, with an immediate market boost in the U.S. and future rollouts in the EU and elsewhere, Goff said.